COVID-19 Rebound? The First Batch of COVID-19 Drugs Is Out!

On July 9th, 2022, China’s first novel Coronavirus neutralizing antibody combination therapy — novel coronavirus balancing antibody combination therapy of Ambavizumab and omalizumab were successfully delivered to The Third People’s Hospital of Shenzhen. On July 11th, the handover ceremony was completed in Shenzhen Third Hospital. This batch of medicine, a total of 100 people, was stored in a cold chain environment of 2-8℃ during the whole process.

Ambayizumab and omalizumab are non-competitive neutralizing monoclonal antibodies of novel Severe Acute respiratory syndrome virus 2(SARS-COV-2) obtained from convalescent COVID-19 patients by Shenzhen Third People’s Hospital. It received marketing approval from the State Medical Products Administration in December 2021 and was commercialized in China on July 7. It is the first domestically developed novel coronavirus antibody drug approved in China.

In March 2022, the combination therapy was approved by the National Health Commission to be included in the COVID-19 Diagnosis and Treatment Protocol (Trial Version 9) for the treatment of adults and adolescents (12-17 years old, Weight ≥40 kg) novel coronavirus infection (COVID-19). Adolescents (12-17 years old, body weight ≥40 kilograms) were conditionally approved.

Data from a previous global Phase 3 clinical trial showed that the combination resulted in a statistically significant 80% reduction in the risk of hospitalization and death in outpatients with high-risk clinical progression of COVID-19 compared with placebo.

Data from live and chimeric virus tests in multiple independent laboratories indicate that amberizumab and omalizumab combination remain neutralizing activity against major novel coronavirus variants of widespread concern, including B.1.1.529-BA.1 (Omicron), And BA.1.1 and BA.2(omicron subtype variant).

Notice

7.12

Four asymptomatic cases

were reported and

The trajectory of the

new cases involved regions

Longhua, Nanshan district

According to the preliminary flow survey, the main activity tracks of new cases in recent days are as follows:

Longhua district

Minzhi Street: Home And Lok Shopping Plaza (Cuiyuan branch), Water World Food spa, Ren Xiaoyao Tea Art, Cuiyuan Convenience store

Nanshan district​

Yuehai Street: Tao Tao Ju (Coastal City store), Hou Hai Express Hotel, Jimmy Convenience Store (Dengliang Road store), Grain Shanghuang (Coastal City business Street store), Green tea restaurant (Coastal City store), Sichuan and Chongqing Malatang (Huaming Road store)

At present, efforts are being made to trace the source of the epidemic, isolate and control the outbreak, conduct nucleic acid testing, and provide medical treatment.

Citizens are urged to continue to fulfill their responsibility for epidemic prevention and control by taking protective measures such as wearing masks, washing hands, ventilation, disinfection, and social distancing, and actively cooperating with the implementation of epidemic prevention and control measures.

Source: SZNews

ARTICLE FROM: AnyShenzhen